Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**RNU6-184P** (RNA, U6 small nuclear 184, pseudogene) is a non-protein-coding gene classified as a pseudogene derived from the U6 small nuclear RNA (snRNA) gene family[5]. U6 snRNAs are highly conserved and central to catalyzing pre-mRNA splicing within the spliceosome[3][1]. However, U6 pseudogenes like RNU6-184P result from genomic duplications or rearrangements and typically do not produce functional RNA products or participate in spliceosome function. There is no evidence that RNU6-184P acts as a receptor, enzyme, transporter, or any other classical therapeutic target, nor that it has a role in disease, interacts with drugs, or serves as a clinical biomarker. Its sequence may retain regions of homology to functional U6 snRNA but lacks regulatory elements or structural integrity necessary for normal function[5][4]. The entry is most likely incorrect as a therapeutic target due to its pseudogene status, its lack of molecular function, and absence from drug-target or disease-biomarker databases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 184, pseudogene (RNU6-184P).